Ping-Ying Pan - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Ping-Ying Pan

Showing results (41-50 of 43) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 43 results.

The Journal of Clinical Investigation|October 24, 2018

Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunityHui-Ming Chen, William van der Touw, Yuan Shuo Wang, et al.

Elife|November 9, 2021

Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modelingJoseph D Butner, Geoffrey V Martin, Zhihui Wang, et al.

Science Translational Medicine|December 15, 2021

A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancerAndrew W Chung, Kartik Anand, Ann C Anselme, et al.

Pageof 5

Search research articles

Showing results (41-50 of 43) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 43 results.

The Journal of Clinical Investigation|October 24, 2018

Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunityHui-Ming Chen, William van der Touw, Yuan Shuo Wang, et al.

Elife|November 9, 2021

Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modelingJoseph D Butner, Geoffrey V Martin, Zhihui Wang, et al.

Science Translational Medicine|December 15, 2021

A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancerAndrew W Chung, Kartik Anand, Ann C Anselme, et al.

Pageof 5